Imlygicc (talimogene laherparepvec) Intralesional
Defines EmblemHealth medical necessity criteria, dosing, limitations, authorization length, applicable codes and ICD-10 diagnoses for intralesional talimogene laherparepvec (Imlygic) for cutaneous melanoma. Includes initial and renewal criteria, exclusions, dosing/administration, maximum units, and billing codes/NDCs.
April 1, 2025 annual review: Updated ICD-10 codes. No criteria changes.
02/16/2024 changes: Initial criteria language revised and name changed to 'Cutaneous Melanoma'.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.